View in EDS HTML Full Text PDF Full Text

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.

Saved in:
Bibliographic Details
Title: COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Authors: Agarwal R; Division of Nephrology, Department of Medicine, Richard L. Roudebush VA Medical Center & Indiana University School of Medicine, Indianapolis, IN, USA., Green JB; Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands., Mann JFE; KfH Kidney Centre, Munich, Germany.; Department of Nephrology & Hypertension, Friedrich Alexander University, Erlangen, Germany., McGill JB; Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine in St. Louis, St Louis, MO, USA., Mottl AK; University of North Carolina Kidney Center, UNC School of Medicine, Chapel Hill, NC, USA., Rosenstock J; Velocity Clinical Research at Medical City, Dallas, TX, USA.; University of Texas Southwestern Medical Center, TX, USA., Rossing P; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Vaduganathan M; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Brinker M; Cardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany., Edfors R; Department of Clinical Sciences, Danderyd University Hospital, Division of Cardiovascular Medicine, Karolinska Institutet, Stockholm, Sweden., Li N; Bayer Healthcare, Chaoyang District, Beijing, China., Scheerer MF; Global Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Scott C; Clinical Statistics and Analytics, Bayer PLC, Reading, UK., Nangaku M; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Corporate Authors: CONFIDENCE investigators
Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2025 Aug 01; Vol. 40 (8), pp. 1559-1569.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium: Internet ISSN: 1460-2385 (Electronic) Linking ISSN: 09310509 NLM ISO Abbreviation: Nephrol Dial Transplant Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39916475
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Agarwal+R%22">Agarwal R</searchLink>; Division of Nephrology, Department of Medicine, Richard L. Roudebush VA Medical Center & Indiana University School of Medicine, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Green+JB%22">Green JB</searchLink>; Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Heerspink+HJL%22">Heerspink HJL</searchLink>; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mann+JFE%22">Mann JFE</searchLink>; KfH Kidney Centre, Munich, Germany.; Department of Nephrology & Hypertension, Friedrich Alexander University, Erlangen, Germany.<br /><searchLink fieldCode="AU" term="%22McGill+JB%22">McGill JB</searchLink>; Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine in St. Louis, St Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Mottl+AK%22">Mottl AK</searchLink>; University of North Carolina Kidney Center, UNC School of Medicine, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Rosenstock+J%22">Rosenstock J</searchLink>; Velocity Clinical Research at Medical City, Dallas, TX, USA.; University of Texas Southwestern Medical Center, TX, USA.<br /><searchLink fieldCode="AU" term="%22Rossing+P%22">Rossing P</searchLink>; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Vaduganathan+M%22">Vaduganathan M</searchLink>; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Brinker+M%22">Brinker M</searchLink>; Cardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Edfors+R%22">Edfors R</searchLink>; Department of Clinical Sciences, Danderyd University Hospital, Division of Cardiovascular Medicine, Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Li+N%22">Li N</searchLink>; Bayer Healthcare, Chaoyang District, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Scheerer+MF%22">Scheerer MF</searchLink>; Global Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Scott+C%22">Scott C</searchLink>; Clinical Statistics and Analytics, Bayer PLC, Reading, UK.<br /><searchLink fieldCode="AU" term="%22Nangaku+M%22">Nangaku M</searchLink>; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22CONFIDENCE+investigators%22">CONFIDENCE investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228706402%22">Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</searchLink> [Nephrol Dial Transplant] 2025 Aug 01; Vol. 40 (8), pp. 1559-1569.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8706402 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1460-2385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209310509%22">09310509 </searchLink><i>NLM ISO Abbreviation: </i>Nephrol Dial Transplant <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39916475
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/ndt/gfaf022
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1559
    Titles:
      – TitleFull: COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Agarwal R
      – PersonEntity:
          Name:
            NameFull: Green JB
      – PersonEntity:
          Name:
            NameFull: Heerspink HJL
      – PersonEntity:
          Name:
            NameFull: Mann JFE
      – PersonEntity:
          Name:
            NameFull: McGill JB
      – PersonEntity:
          Name:
            NameFull: Mottl AK
      – PersonEntity:
          Name:
            NameFull: Rosenstock J
      – PersonEntity:
          Name:
            NameFull: Rossing P
      – PersonEntity:
          Name:
            NameFull: Vaduganathan M
      – PersonEntity:
          Name:
            NameFull: Brinker M
      – PersonEntity:
          Name:
            NameFull: Edfors R
      – PersonEntity:
          Name:
            NameFull: Li N
      – PersonEntity:
          Name:
            NameFull: Scheerer MF
      – PersonEntity:
          Name:
            NameFull: Scott C
      – PersonEntity:
          Name:
            NameFull: Nangaku M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1460-2385
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
              Type: main
ResultId 1